Harmony Biosciences Appoints Experienced Glenn Reicin as CFO; Reaffirms Strong 2026 Revenue Guidance
Summary
Harmony Biosciences announced the departure of its CFO, Sandip Kapadia, and the immediate appointment of Glenn Reicin, a seasoned biopharmaceutical executive, as his successor, while also reaffirming its 2026 revenue guidance.
Key Events
-
CFO Sandip Kapadia Departs
Sandip Kapadia stepped down as Chief Financial Officer, effective April 14, 2026, to pursue other career opportunities. He will receive a severance package including a $539,000 lump sum, COBRA payments, outplacement services, and accelerated vesting of certain equity awards.
-
Glenn Reicin Appointed as New CFO
Glenn Reicin was appointed as the new Chief Financial Officer, effective April 14, 2026. Mr. Reicin brings extensive experience from previous CFO roles at Eccogene, Alladapt Immunotherapeutics, and Sigilon Therapeutics, as well as a background in equity research and venture capital.
-
New CFO Compensation Package
Mr. Reicin's compensation includes an annual base salary of $500,000, a target annual bonus of 50% of his base salary, and an initial stock option award with a grant date fair value of $3,000,000, vesting over four years.
-
2026 Revenue Guidance Reaffirmed
The company reiterated its 2026 net product revenue guidance of $1.0 billion to $1.04 billion, signaling confidence in its financial outlook. This reaffirmation was previously reported by Dow Jones Newswires on the same day.
Analysis
This filing details a significant C-suite transition at Harmony Biosciences, with the departure of its CFO and the immediate appointment of a highly experienced successor. The incoming CFO, Glenn Reicin, brings a strong background in biopharmaceutical finance, capital markets, and strategic planning, which is a positive for the company's leadership stability and future financial strategy. The reaffirmation of robust 2026 revenue guidance provides a confident backdrop to this executive change, suggesting continued operational strength despite the leadership transition. Investors should monitor the integration of the new CFO and any subsequent strategic initiatives.
At the time of this filing, HRMY was trading at $28.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $25.52 to $40.87. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.